Thus, HDAC inhibitors are considered promising agents for cancer treatment, and four HDAC inhibitors have been approved for clinical use in T-cell lymphoma and multiple myeloma therapies. Here, HDAC9 is linked to T-cell non-Hodgkin lymphoma.